Press Releases

Biocon Biologics  /  Press Releases

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options

  • Posted by: Biocon Biologics

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars

  • Posted by: Biocon Biologics

Biocon Biologics’ Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases

  • Posted by: Biocon Biologics

Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars

  • Posted by: Biocon Biologics

Biocon Foundation Supports Government High School, Kicks off Construction of a New Building for 250 Students

  • Posted by: Biocon Biologics

Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15%

  • Posted by: Biocon Biologics

Deepali Naair Appointed as the Global Head – Brand & Corporate Communications at Biocon Biologics

  • Posted by: Biocon Biologics

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States

  • Posted by: Biocon Biologics

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

  • Posted by: Biocon Biologics

Biocon Biologics Expands Insulin Access in Malaysia

  • Posted by: Biocon Biologics
Share
buy twitter followers - deneme bonusu veren siteler - deneme bonusu veren siteler - deneme bonusu veren siteler - deneme bonusu veren siteler - takipcimx 1000 - buy facebook followers -

çekişmeli boşanma avukatı

- volgers kopen - Antalya vip transfer